

## FAST FACTS

# Prostate Cancer


*Up-to-date insights on disease, treatment, and care based on real-world data from Komodo's full-stack healthcare analytics platform*

**Prostate cancer is the second most common cancer in American men and will affect about 13% of males in their lifetime.**

Most cases of prostate cancer are asymptomatic, and 69% are diagnosed at a localized stage after an elevated PSA result or abnormal physical exam. The five-year survival rate for prostate cancer diagnosed at

this early stage is 100%. This number drops to 34% for Stage IV metastatic cases, for which new therapeutic options have been recently introduced. Research on low-risk cases has reshaped patient treatment pathways over the past decade; today, nearly 60% of men with low-risk prostate cancer now choose active surveillance over treatment.

## DEMOGRAPHICS



**States with the highest prevalence of prostate cancer (by population)**

- 1 Delaware
- 2 Florida
- 3 New Jersey
- 4 Michigan
- 5 New York

## SYMPTOMS AND COMORBIDITIES



### Most common associated signs and symptoms

1. Benign prostatic hyperplasia
2. Urinary tract infections
3. Low-back pain
4. Anemia
5. Erectile dysfunction



### Most common comorbidities prior to diagnosis

1. Hypertension
2. Hyperlipidemia
3. Type 2 diabetes
4. Urinary tract infections

## DIAGNOSIS



### Top diagnosing specialties

1. Urology
2. Internal Medicine
3. Family Practice



### Most common diagnostic procedures


1. Prostate specific antigen (PSA) measurement
2. Automated urinalysis test
3. Biopsy of prostate gland

## MOST FREQUENTLY UTILIZED THERAPIES

**Hormone therapy** (bicalutamide or leuprolide acetate) is the primary form of treatment for hormone-sensitive prostate cancer.

**Poly-ADP ribose polymerase (PARP)** inhibitors are on the rise after recent approvals and a push for personalized precision medicine.

### Percentage of Market Share Among Chemotherapeutic Agents and PARP Inhibitors



The market share of **PARP inhibitors** increased by **nearly 40%** within a given year. Conversely, the market share of **chemotherapeutics** year over year dropped **nearly 50%**, which could have been a result of the 2020 approval for olaparib and rucaparib to treat some types of metastatic castration-resistant prostate cancer.

Komodo Health "Fast Facts" are derived from the Komodo Healthcare Map™, the largest and most complete database of de-identified, real-world patient data. The Healthcare Map uses artificial intelligence and advanced analytics to track the individual encounters with the healthcare system of over 330 million patients. Drawing data from both providers and payers, the Healthcare Map is the only database of its kind to provide a longitudinal view of the entire patient journey — whether care was delivered in-network or out-of-network and through a specialist, an urgent care center, or a retail clinic. The data in this "Fast Facts" report represents the latest real-world patient data from October 2015 to May 2023.

How to cite this information: Source: Komodo Health, "Fast Facts: Prostate Cancer," 2023.

